Peptide Companion Diagnostic Development: Market Growth and Strategic Opportunities

Companion diagnostics are changing how doctors choose treatments for patients.

And in the peptide therapy world, these diagnostic tests are becoming more important every year.

A companion diagnostic is a test that helps doctors figure out if a specific drug will work for a specific patient.

When paired with peptide therapies, these tests can make treatment safer and more effective.

What Are Companion Diagnostics?

A companion diagnostic (CDx) is a medical test that gives information about whether a particular treatment is right for a patient.

It might look for a specific protein, gene mutation, or biomarker in a patient's blood or tissue.

If the biomarker is present, the patient is more likely to benefit from the therapy. If not, the doctor can choose a different treatment.

This is the heart of precision medicine. The right drug for the right patient at the right time.

Why Peptide Therapies Need Companion Diagnostics

Peptide drugs are highly targeted. They bind to specific receptors or proteins in the body.

But not every patient has those targets. And not every tumor expresses the right receptors.

Without a diagnostic test, doctors are guessing about whether a peptide therapy will work.

Companion diagnostics remove that guesswork.

Here is a clear example. Peptide receptor radionuclide therapy (PRRT) targets somatostatin receptors on neuroendocrine tumors. Before giving PRRT, doctors use imaging scans to confirm the tumor expresses those receptors.

Without that scan, the therapy might be given to patients who will not benefit.

That wastes money and exposes patients to unnecessary side effects.

"The future of peptide therapeutics is inseparable from companion diagnostics. You cannot deliver precision medicine without precision diagnosis," says Dr. Sarah Chen, a molecular diagnostics specialist.

The FDA now requires companion diagnostic approval alongside more than 40% of new targeted therapy applications, up from just 10% a decade ago.

Market Size and Growth Projections

The companion diagnostic market is booming.

Metric	Value
Global CDx market size (2025)	$7.2 billion
Projected market size (2030)	$14.8 billion
Compound annual growth rate	15.5%
Peptide-related CDx share	8-12% of total market

The peptide-specific segment is growing even faster than the overall market.

This is driven by the expanding pipeline of peptide therapeutics in oncology, endocrinology, and rare diseases.

The FDA now requires companion diagnostics for many new drug approvals. Over 50 companion diagnostics have been approved alongside their partner therapies in the last decade.

Types of Companion Diagnostics for Peptide Therapies

Different peptide therapies need different types of tests.

Imaging-Based Diagnostics

These use radioactive tracers to visualize targets in the body.

Gallium-68 DOTATATE PET scans are a perfect example. They show exactly where somatostatin receptors are located, helping doctors plan PRRT treatment.

Imaging diagnostics are especially important for peptide-based cancer therapies.

Tissue-Based Diagnostics

These tests analyze tumor samples taken during biopsy.

Immunohistochemistry (IHC) staining can reveal whether a tumor expresses the protein that a peptide drug targets.

These tests are widely used and relatively affordable.

Blood-Based Diagnostics (Liquid Biopsy)

Blood tests that detect circulating biomarkers are becoming more popular.

They are less invasive than tissue biopsies and can be repeated easily to monitor treatment response.

For peptide therapies, liquid biopsies might measure circulating tumor DNA, protein markers, or peptide hormone levels.

Genetic Tests

Some companion diagnostics look for specific gene mutations or variations.

These tests help predict whether a patient's body will respond to a peptide drug based on their genetic makeup.

Pharmacogenomic testing is growing in importance for personalized peptide therapy.

Regulatory Requirements

Regulatory agencies take companion diagnostics seriously.

The FDA's guidance on companion diagnostics states that these tests should be developed alongside the drugs they support.

This means drug companies and diagnostic companies need to work together from the early stages of development.

Key regulatory points include:

• The CDx and the drug should be submitted for approval at the same time when possible
• Clinical trials should include the companion diagnostic as part of patient selection
• The CDx must demonstrate analytical validity, clinical validity, and clinical utility
• Post-market surveillance is required for both the drug and the diagnostic

In Europe, the In Vitro Diagnostic Regulation (IVDR) has added new requirements that make CDx development more complex but also more standardized.

Companies that understand these requirements early save time and money during development.

Strategic Partnerships Between Drug and Diagnostic Companies

No peptide company can do it all alone.

Developing a companion diagnostic requires expertise in molecular biology, assay development, regulatory science, and manufacturing.

Most peptide drug companies partner with established diagnostic firms.

Some common partnership models include:

• Co-development agreements where both companies share costs and risks
• Licensing deals where a diagnostic company gets rights to develop a test based on the drug company's biomarker data
• Acquisition where a drug company buys a diagnostic firm to bring the capability in-house
• Platform partnerships where multiple drug companies use the same diagnostic platform for different peptide therapies

These partnerships need to start early. Waiting until Phase III clinical trials to think about companion diagnostics is too late.

Impact on Clinical Trial Design

Companion diagnostics change how clinical trials are designed and run.

Patient selection becomes more precise. Only patients who test positive for the target biomarker are enrolled.

This makes trials smaller and more efficient because you are studying a population more likely to respond.

Enrichment designs are becoming standard. These trials use the companion diagnostic to screen patients before randomization.

Adaptive designs allow the diagnostic criteria to be refined as data comes in during the trial.

The result is faster trials, clearer results, and a higher chance of regulatory approval.

For more on how clinical trials are evolving in the peptide space, read our article on peptide AI clinical trial design.

Economic Value of Companion Diagnostics

Companion diagnostics create value for everyone in the healthcare system.

For patients, CDx means getting the right treatment the first time. No wasted months on drugs that will not work.

For payers, CDx reduces spending on ineffective treatments. A $500 diagnostic test can prevent tens of thousands of dollars in wasted therapy costs.

For drug companies, CDx improves clinical trial success rates and supports premium pricing. A drug with a companion diagnostic that identifies responders can command a higher price because it delivers better outcomes.

For healthcare systems, CDx reduces hospitalizations and side effect management costs.

Stakeholder	Value Created
Patients	Better outcomes, fewer side effects
Payers	Reduced waste on ineffective treatments
Drug companies	Higher approval rates, premium pricing
Healthcare systems	Lower total cost of care

Technology Advances Driving CDx Development

Several technology trends are making companion diagnostics better and cheaper.

Next-generation sequencing (NGS) allows comprehensive genetic profiling from a single sample. This can identify multiple biomarkers at once.

Digital pathology uses AI to analyze tissue samples faster and more consistently than human pathologists.

Multiplexed assays test for many biomarkers simultaneously, giving a complete picture of a tumor's biology.

Point-of-care testing brings diagnostic capability to the clinic, reducing turnaround time from days to hours.

These advances lower the cost and complexity of companion diagnostic development.

Challenges in CDx Development

Despite the growth, there are real challenges.

• Biomarker identification is hard. Not every peptide drug has a clear biomarker that predicts response
• Assay standardization across different labs and platforms remains difficult
• Regulatory timelines for CDx and drug co-approval do not always align
• Reimbursement for diagnostic tests varies widely by country and payer
• Sample availability from clinical trials may be limited for CDx validation

Companies need experienced teams to navigate these challenges.

Building or hiring companion diagnostic expertise early in the drug development process is critical.

For insights on building the right team, explore our guide on biotech talent acquisition strategy.

The Future of Peptide Companion Diagnostics

Looking ahead, several trends will shape this market.

Multi-biomarker panels will replace single-biomarker tests. These panels will help doctors choose between multiple peptide therapy options.

Real-time monitoring diagnostics will track treatment response and guide dose adjustments.

AI-powered diagnostics will combine imaging, genetic, and clinical data to predict peptide therapy outcomes.

Decentralized testing will allow companion diagnostics to be performed at community clinics, not just major medical centers.

Companion diagnostics for biosimilars will emerge as peptide biosimilars enter the market and need to demonstrate equivalent targeting.

The peptide companion diagnostic market will continue to grow as precision medicine becomes the standard of care.

Studies show that cancer patients treated with biomarker-guided therapy have a 30 percent higher response rate on average compared to those treated without biomarker selection. For peptide therapies with clear receptor targets, that number can be even higher.

Frequently Asked Questions

What is a companion diagnostic?

A companion diagnostic is a medical test used alongside a specific drug to determine if that drug is appropriate for a particular patient. It identifies biomarkers that predict treatment response.

Why are companion diagnostics important for peptide therapies?

Peptide drugs target specific receptors or proteins. Companion diagnostics confirm that a patient's disease expresses those targets, ensuring the therapy is given to patients most likely to benefit.

Who develops companion diagnostics?

Companion diagnostics are typically developed by diagnostic companies in partnership with pharmaceutical or biotech companies. Some larger companies develop both the drug and the diagnostic in-house.

How much does a companion diagnostic test cost?

Costs vary widely depending on the type of test. Simple immunohistochemistry tests may cost a few hundred dollars. Advanced genomic panels can cost $1,000 to $5,000 or more.

Are companion diagnostics required by the FDA?

The FDA strongly encourages co-development of companion diagnostics with new drugs. In many cases, a CDx is required for drug approval, especially when the drug is intended for a biomarker-defined patient population.

How long does it take to develop a companion diagnostic?

Development typically takes 3 to 5 years, though it can be longer for complex diagnostics. Starting CDx development early in the drug development process is critical to avoid delays.

What career opportunities exist in the CDx field?

The field needs molecular biologists, assay development scientists, regulatory affairs specialists, bioinformaticians, clinical trial managers, and commercial strategists. Demand for these roles is growing rapidly.